...
首页> 外文期刊>Journal of neuro-oncology. >Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.
【24h】

Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.

机译:不懈的进步:放射外科和放射疗法在中枢神经系统肿瘤治疗方面的最新进展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In the past decade, our understanding of the roles of external beam radiotherapy (EBRT) and stereotactic radiosurgery (SRS) in the management of brain tumors has dramatically improved. To highlight the changes and contemporary treatment approaches, we review the indications and outcomes of ionizing radiation for benign intracranial tumors and brain metastases. For nonfunctioning pituitary adenomas, SRS is able to achieve radiographic tumor control in at least 90 % of cases. The rate of SRS-induced endocrine remission for functioning pituitary adenomas depends on the tumor subtype, but it is generally lower than the rate of radiographic tumor control. The most common complications from pituitary adenoma SRS treatment are hypopituitarism and cranial neuropathies. SRS has become the preferred treatment modality for vestibular schwannomas and skull base meningiomas less than 3 cm in size. Large vestibular schwannomas and meningiomas remain best managed with initial surgical resection or EBRT for surgically ineligible patients. For small to moderately sized brain metastases, there has been a shift toward treatment of newly diagnosed patients with SRS alone due to similar local control rates compared with surgical resection. RCTs have shown combined SRS and whole brain radiation therapy (WBRT) for brain metastases to decrease rates of local and distant intracranial recurrence compared to SRS alone. However, the improved intracranial control comes at the expense of poorer neurocognitive outcomes and without prolonging overall survival. Therefore, WBRT is generally reserved for salvage therapy. While EBRT has been frequently supplanted by SRS for the treatment pituitary adenomas and brain metastases, it still proves useful in selected cases of large lesions which are not amenable to surgical debulking or for those with widespread disease, poor performance status, and short life expectancy. In recent years, the scope of SRS has extended beyond the intracranial space to include extradural and intradural spinal tumors.
机译:在过去的十年中,我们对外部束放射疗法(EBRT)和立体定向放射外科手术(SRS)在脑肿瘤治疗中的作用的了解已大大提高。为了强调变化和当代治疗方法,我们回顾了良性颅内肿瘤和脑转移的电离辐射的适应症和结果。对于无功能的垂体腺瘤,SRS能够在至少90%的病例中实现影像学上的肿瘤控制。 SRS引起的功能性垂体腺瘤的内分泌缓解率取决于肿瘤亚型,但通常低于放射线照相肿瘤控制率。垂体腺瘤SRS治疗最常见的并发症是垂体功能低下和颅神经病变。 SRS已成为尺寸小于3 cm的前庭神经鞘瘤和颅底脑膜瘤的首选治疗方式。对于不适合外科手术的患者,大的前庭神经鞘瘤和脑膜瘤仍可通过初始手术切除或EBRT进行最佳处理。对于中小规模的脑转移,由于局部控制率与手术切除率相近,因此已转向仅对新诊断的SRS患者进行治疗。 RCTs显示,与单独的SRS相比,SRS和全脑放射疗法(WBRT)联合治疗脑转移可降低局部和远距离颅内复发率。然而,改进的颅内控制以较差的神经认知结果为代价,并且不会延长总生存期。因此,WBRT通常保留用于抢救治疗。虽然EBRT经常被SRS取代以治疗垂体腺瘤和脑转移瘤,但它仍然被证明在某些大的病变病例中有用,这些病例不适合手术切除或对于那些疾病广泛,表现状态差和预期寿命短的患者。近年来,SRS的范围已超出颅内空间,包括硬膜外和硬膜内脊柱肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号